Gary W Boyle
Overview
Explore the profile of Gary W Boyle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weston D, Thomas S, Boyle G, Pieren M
Drug Metab Dispos
. 2024 May;
52(8):858-874.
PMID: 38769017
Alpibectir (also known as BVL-GSK098 and GSK3729098) is a new chemical entity (NCE) with a novel mechanism for the treatment of tuberculosis. The disposition of alpibectir was determined in subjects...
2.
Pieren M, Abaigar Gutierrez-Solana A, Antonijoan Arbos R, Boyle G, Davila M, Davy M, et al.
J Antimicrob Chemother
. 2024 Apr;
79(6):1353-1361.
PMID: 38656557
Background: The clinical candidate alpibectir augments the activity of, and overcomes resistance to, the anti-TB drug ethionamide in vitro and in vivo. Objectives: A Phase 1, double-blind, randomized, placebo-controlled study...
3.
Nuermberger E, Martinez-Martinez M, Sanz O, Urones B, Esquivias J, Soni H, et al.
Antimicrob Agents Chemother
. 2022 May;
66(6):e0013222.
PMID: 35607978
As a result of a high-throughput compound screening campaign using Mycobacterium tuberculosis-infected macrophages, a new drug candidate for the treatment of tuberculosis has been identified. GSK2556286 inhibits growth within human...
4.
Flipo M, Frita R, Bourotte M, Martinez-Martinez M, Boesche M, Boyle G, et al.
Sci Transl Med
. 2022 May;
14(643):eaaz6280.
PMID: 35507672
The sensitivity of , the pathogen that causes tuberculosis (TB), to antibiotic prodrugs is dependent on the efficacy of the activation process that transforms the prodrugs into their active antibacterial...
5.
Dave M, Nash M, Young G, Ellens H, Magee M, Roberts A, et al.
Drug Metab Dispos
. 2014 Jan;
42(3):415-30.
PMID: 24378325
The absorption, metabolism, and excretion of darapladib, a novel inhibitor of lipoprotein-associated phospholipase A2, was investigated in healthy male subjects using [(14)C]-radiolabeled material in a bespoke study design. Disposition of...